Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-Deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy.

Trial Profile

Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-Deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Everolimus (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Oct 2012 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 17 Oct 2011 Planned End Date changed from 1 Apr 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top